Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

Next Previous
X
Search
Trial Profile

A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orforglipron (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 06 Oct 2023 Results comparing the efficacy, safety, and tolerability of OFG in patients with obesity or overweight with weight related comorbidity, presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
    • 23 Aug 2023 The protocol has been amended as above-1) Number of treatment has been changed from 5 to 7.2) primary endpoint has been amended.
    • 26 Jun 2023 Results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top